IDP:FRA
Biogen Inc
€198.26
arrow_downward
-0.52%(-1.04) 1D
Sep 30, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IDP...
Open
€198.50
High
€198.50
Low
€198.26
Mkt. cap
33.37B
Avg. vol.
27.00
Volume
0.00
52-wk high
€200.85
52-wk low
€114.90
No. of employees
8K
Open
€198.50
High
€198.50
Low
€198.26
Mkt. cap
33.37B
Avg. vol.
27.00
Volume
0.00
52-wk high
€200.85
52-wk low
€114.90
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
1 day ago
Biogen stock after-hours at EUR 200.20: minus 0.22 percent versus prior close
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com